Clear All
796 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
N/A Zongertinib HERNEXEOS 60mg Chemotherapy Tyrosine Kinase Inhibitor HER2 Yes 2025 In Use
N/A Ensartinib ENSACOVE 25mg, 100mg Chemotherapy Tyrosine Kinase Inhibitor ALK, ROS1, MET Yes 2025 In Use
J9275 Cosibelimab-ipdl UNLOXCYT 2mg Immunotherapy Checkpoint Inhibitor PD-L1 No 2025 Jul 9, 2025 In Use
J9011 Datopotamab Deruxtecan Datroway 1mg Immunotherapy Drug Antibody Conjugate Topoisomerase I, TROP2 No 2025 Sep 8, 2025 In Use
N/A Imlunestrant Inluriyo 200mg Hormonal Therapy Estrogen Receptor Antagonist ER⍺ Yes 2025 In Use
C9306 Telisotuzumab vedotin-tllv Emrelis 1mg Immunotherapy Drug Antibody Conjugate c-MET No 2025 2026 Sep 8, 2025 Jan 12, 2026 In Use
J9326 Telisotuzumab vedotin-tllv Emrelis 1mg Immunotherapy Drug Antibody Conjugate c-MET No 2025 Jan 12, 2026 In Use
N/A Avutometinib potassium and defactinib hydrochloride AVMAPKI FAKZYNJA CO-PACK 0.8mg and 200mg Chemotherapy MEK Inhibitor, Tyrosine Kinase Inhibitor MEK1/2, ERK1/2, KRAS Yes 2025 In Use
N/A Calcium folinate Lederle Leucovorin 5mg Ancillary Therapy Chemoprotective Antidote Yes 2025 In Use
J9277 Pembrolizumab and berahyaluronidase alfa-pmph KEYTRUDA QLEX 1mg Immunotherapy Checkpoint Inhibitor PD-1 No 2025 Mar 18, 2026 In Use
N/A Ziftomenib Komzifti 200mg Chemotherapy Enzyme Inhibitor KMT2A Yes 2025 In Use
Q5159 Denosumab-dssb Ospomyv, Xbryk 1mg Immunotherapy Monoclonal Antibody RANKL No 2025 Sep 8, 2025 In Use
J0614 Treosulfan Grafapex 50mg Chemotherapy Alkylating Agent Alkyl Sulfonate No 2025 Sep 8, 2025 In Use
N/A Zidesamtinib Jideytro 25mg, 100mg Chemotherapy Tyrosine Kinase Inhibitor ROS1, ALK, TRK Yes 2026 In Use
C9310 Leucovorin calcium ( avyxa) Vykoura 1mg Ancillary Therapy Chemoprotective Antidote No 2026 Jun 17, 2026 In Use
N/A Vepdegestrant Veppanu 100mg, 200mg Hormonal Therapy Proteolysis Targeting Chimera (PROTAC) ER, Cereblon/CRBN Yes 2026 In Use
N/A Relacorilant Lifyorli 25mg, 100mg Chemotherapy Glucocorticoid Receptor (GR) Antagonist Yes 2026 In Use
Q5167 Denosumab-qbde Enoby/Xtrenbo 1mg Immunotherapy Monoclonal Antibody RANKL No 2026 Jun 17, 2026 In Use
Q5166 Denosumab-desu Jubereq, Osvyrti 1mg Immunotherapy Monoclonal Antibody RANKL No 2026 Jun 17, 2026 In Use
Q5169 Pegfilgrastim-unne Armlupeg 0.5mg Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor No 2026 Jun 17, 2026 In Use
Q5162 Denosumab-nxxp Bildyos/Bilprevda 1mg Immunotherapy Monoclonal Antibody RANKL No 2026 Mar 18, 2026 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.